Diet, Exercise Intervention Explored in Children With B-ALL
THURSDAY, April 8, 2021 -- For children with B-cell acute lymphoblastic leukemia (B-ALL), a diet and exercise intervention might improve disease response, according to a study published online April 1 in Blood Advances. Etan Orgel, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2021 Category: Pharmaceuticals Source Type: news

What are the risk factors for experiencing side effects from childhood cancer treatments?
(Wiley) Steroids are essential for treating children with acute lymphoblastic leukemia, a type of cancer of the blood and bone marrow, but they can cause severe side effects such as psychological reactions and sleep problems. An analysis published in Psycho-Oncology of all relevant studies published to date indicates that there's insufficient high-quality research investigating the risk factors for these side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 7, 2021 Category: International Medicine & Public Health Source Type: news

Adding in Stem Cell Therapy Helps Beat a Common Childhood Leukemia
FRIDAY, April 2, 2021 -- Combining stem cell transplants with cutting-edge immunotherapy prevents leukemia relapses in young people and improves their chances of survival, new research suggests. Acute lymphoblastic leukemia is the most common... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 2, 2021 Category: General Medicine Source Type: news

Low-calorie diet and mild exercise improve survival for young people with leukemia
In some cancers, including leukemia in children and adolescents, obesity can negatively affect survival outcomes. Obese young people with leukemia are 50% more likely to relapse after treatment than their lean counterparts.Now,a study led by researchers at UCLA and Children’s Hospital Los Angeles has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.The researchers found that patients who reduced their calorie intake by 10% or more and adopted a moderate exercise program imm...
Source: UCLA Newsroom: Health Sciences - April 1, 2021 Category: Universities & Medical Training Source Type: news

Stem cell transplants prevent relapses of most common childhood cancer
(University of Virginia Health System) Children and young adults who receive CAR T-cell therapy for the most common childhood cancer - acute lymphoblastic leukemia - suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2021 Category: Cancer & Oncology Source Type: news

Low-calorie diet and mild exercise improve survival for young people with leukemia
(University of California - Los Angeles Health Sciences) A study led by researchers at UCLA and CHLA has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2021 Category: Cancer & Oncology Source Type: news

Crnic Institute discovery may explain high risk of leukemia in children with Down syndrome
(University of Colorado Anschutz Medical Campus) Children with Down syndrome are 20-times more likely to develop acute lymphocytic leukemia (ALL) and 150-times more likely to develop acute myeloid leukemia (AML) compared to their typical peers. According to a new study by researchers at the Linda Crnic Institute for Down Syndrome, the reason could be that children with Down syndrome are more likely to present with clonal hematopoiesis (CH), a process in which a blood stem cell acquires a genetic mutation that promotes replication. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
DUBLIN, March 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos® (daunorubicin and cytarabine) to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 30, 2021 Category: Drugs & Pharmacology Source Type: news

Consumer Health: Treating acute lymphocytic leukemia
Acute lymphocytic leukemia is a cancer of the blood and bone marrow. It's the most common type of cancer in children, and treatment results in a good chance for a cure. Acute lymphocytic leukemia also can occur in adults, though the chance of a cure is reduced greatly. Signs and symptoms of acute lymphocytic leukemia [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 29, 2021 Category: Databases & Libraries Source Type: news

Risk Factors Predict Graft Failure in Pediatric Acute Leukemia Patients Risk Factors Predict Graft Failure in Pediatric Acute Leukemia Patients
Researchers have developed a predictive score for the risk of graft failure in patients with acute leukemia who undergo allogeneic hematopoietic stem cell transplantation with ex vivo T-cell depletion.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 25, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Virginia Commonwealth University Scientists Combine dPCR and High-Speed Microscopic Imaging to Reduce Cost of Diagnosing Cancers
VCU scientists used the technique to measure mutations associated with acute myeloid leukemia, potentially offering an attractive alternative to DNA sequencing More accurate but less-costly cancer diagnostics are the Holy Grail of cancer research. Now, research scientists at Virginia Commonwealth University (VCU) say they have developed a clinical laboratory diagnostic technique that could be far […] The post Virginia Commonwealth University Scientists Combine dPCR and High-Speed Microscopic Imaging to Reduce Cost of Diagnosing Cancers appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - March 24, 2021 Category: Laboratory Medicine Authors: Jude Tags: Digital Pathology Instruments & Equipment Laboratory Instruments & Laboratory Equipment Laboratory Management and Operations Laboratory Operations Laboratory Pathology Laboratory Testing Management & Operations ACS Alden Chesney MD ame Source Type: news

Drug Trial Snapshot: DAURISMO
DAURISMO is used to treat adults with newly-diagnosed acute myeloid leukemia (AML). It is to be used in patients who•are 75 years of age or older, or•have other medical conditions that prevent the use of standard chemotherapy. AML is a rapidly progressing cancer that forms in the bone marrow and (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 18, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Whole-Genome Sequencing Is Accurate for Myeloid Cancers
WEDNESDAY, March 10, 2021 -- A streamlined whole-genome sequencing approach can provide rapid and accurate genomic profiling for acute myeloid leukemia (AML) or myelodysplastic syndromes, according to a study published in the March 11 issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 10, 2021 Category: Pharmaceuticals Source Type: news

Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 4, 2021 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

Genetic Mutations May Add to Racial Disparity in Child B-ALL
FRIDAY, Feb. 19, 2021 -- Hispanic/Latino (H/L) children with B-cell acute lymphoblastic leukemia (B-ALL) have an increased incidence of IKZF1 deletion and IGH-CRLF2 translocation, according to a letter to the editor published online Feb. 2 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2021 Category: Pharmaceuticals Source Type: news

New classification of leukemia subtypes reveals potential of existing drugs
(University Health Network) Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) - called NPM1 - that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 16, 2021 Category: International Medicine & Public Health Source Type: news

Researchers take early step toward leukemia drug therapy
(McMaster University) The team has discovered that for acute myeloid leukemia (AML) patients, there is a dopamine receptor pathway that becomes abnormally activated in the cancer stem cells. This inspired the clinical investigation of a dopamine receptor-inhibiting drug thioridazine as a new therapy for patients, and their focus on adult AML has revealed encouraging results. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news

Sinai team builds first model acute myeloid leukemia progression using CRISPR
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A research team led by the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) has built the first cellular model to depict the evolution of acute myeloid leukemia (AML), from its early to late stages. By using gene editing technologies to alter genes that make cells malignant, the team was able to identify potential therapeutic targets for early disease stages. The study was reported in the journal Cell Stem Cell in February. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2021 Category: Cancer & Oncology Source Type: news

TBI Beats Chemoconditioning for ALL Transplants in Children TBI Beats Chemoconditioning for ALL Transplants in Children
Total body irradiation (TBI) plus etoposide remains the conditioning regimen of choice for children undergoing transplant for acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New maintenance treatment for acute myeloid leukemia prolongs the lives of patients
(Weill Cornell Medicine) Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2021 Category: Cancer & Oncology Source Type: news

New drug combination shows promise as powerful treatment for AML
(Sanford Burnham Prebys Medical Discovery Institute) Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone. The researchers were able to significantly enhance cancer cell death by jointly administering the drugs that are only partially effective when used as single-agent therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 19, 2021 Category: Cancer & Oncology Source Type: news

Leukemia: New Adverse Event With PARP Inhibitors in Cancer Leukemia: New Adverse Event With PARP Inhibitors in Cancer
Late toxicities in the form of myelodysplastic syndrome and acute myeloid leukemia can occur even a brief exposure to PARP inhibitors, and both are associated with a high mortality rate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

Key Presentations on Acute Myeloid Leukemia From ASH 2020 Key Presentations on Acute Myeloid Leukemia From ASH 2020
Highlights in acute myeloid leukemia from ASH 2020 include study results for combination therapy in newly diagnosed AML patients with FLT-3, and CPX-351 vs 7 + 3 in older adults with secondary or high-risk-prognosis AML.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Oral Azacitidine Benefits Some Older Adults With AML
TUESDAY, Dec. 29, 2020 -- For older patients with acute myeloid leukemia (AML) who are in remission after chemotherapy, those receiving maintenance therapy with the oral formulation of azacitidine (CC-486) versus placebo had longer overall and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 29, 2020 Category: Pharmaceuticals Source Type: news

Highlights in Acute Lymphoblastic Leukemia From ASH 2020 Highlights in Acute Lymphoblastic Leukemia From ASH 2020
Key studies from ASH 2020 on acute lymphoblastic leukemia include novel CAR T-cells, antibody-based therapies sequenced with chemotherapy, and residual disease monitoring with peripheral blood.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Drug offers hope for acute myeloid leukemia treatment in older adults
A new drug treatment for acute myeloid leukemia improves overall survival in those with the deadly blood cancer by up to 10 months, according to a clinical trial published by the New England Journal of Medicine. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 24, 2020 Category: Consumer Health News Source Type: news

Global trial reveals life saving drug for acute myeloid leukemia
(Monash University) Results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML), significantly improving survival in older patients, over the age of 55, with the disease. AML is the most acute blood cancer in adults and its incidence increases with age, with a poor prognosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 23, 2020 Category: Cancer & Oncology Source Type: news

Astellas Reports XOSPATA(R) (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
TOKYO, Dec. 21, 2020 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that a Phase 3 trial of XOSPATA® (gilteritinib) plus azacitidine versus ... Biopharmaceuticals, Oncology Astellas Pharma, XOSPATA, gilteritinib, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 21, 2020 Category: Pharmaceuticals Source Type: news

Novel combination therapy may help overcome mTOR drug resistance in AML
(Cincinnati Children's Hospital Medical Center) Despite high hopes, mTOR inhibitors have not shown much success against acute myeloid leukemia. But a study in PNAS led by experts at Cincinnati Children's suggests a combination therapy may prove more effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 21, 2020 Category: Cancer & Oncology Source Type: news

Integrated Palliative and Oncology Care Improves QOL in Leukemia
FRIDAY, Dec. 18, 2020 -- For patients with acute myeloid leukemia (AML) receiving intensive chemotherapy, there are substantial improvements in quality of life (QOL) and psychological distress with integrated palliative and oncology care (IPC),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2020 Category: Pharmaceuticals Source Type: news

Palliative care improves quality of life for patients with advanced blood cancer
(Massachusetts General Hospital) A first-of-its-kind intervention integrating palliative care early in the course of cancer therapy for patients with advanced acute myeloid leukemia (AML), a highly aggressive cancer of the blood and bone marrow, resulted in substantial improvements in patients' quality of life, mood and end-of-life care, a team of investigators has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

Why Do Black Patients Fare Worse With Blood Cancer Than Whites?
FRIDAY, Dec. 11, 2020 -- A pair of studies shed new light on why a relatively rare blood cancer— acute myeloid leukemia (AML)— is more deadly among Black patients. The takeaways: Where patients live and their access to quality health... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 11, 2020 Category: General Medicine Source Type: news

ASH: Black Race Linked to Poorer Survival in AML
TUESDAY, Dec. 8, 2020 -- Self-reported patient race is the most important factor associated with poorer survival in patients with acute myeloid leukemia (AML), according to a study presented at the annual meeting of the American Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2020 Category: Pharmaceuticals Source Type: news

Chemotherapy and blinatumomab improves survival for patients with B-cell acute lympho
(University of Texas M. D. Anderson Cancer Center) A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very hig...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Patti Payne: AML survivor returns home after bone marrow transplant, grateful for milestones
What ’s on your gratitude list for Thanksgiving and into the holidays? In the face of life-threatening challenges Ryan Dwyer, 40, is grateful for a long list of things. Gratitude is at the very fiber of his being. This Kenmore man just underwent a bone marrow transplant for acute myeloid leukemia — his second round of this aggressive disease. He thought he beat it the first time, but learned in mid-2020 it had returned with a vengeance, and thus the more drastic treatment was needed. Dwyer… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 25, 2020 Category: Biotechnology Authors: Patti Payne Source Type: news

Patients and Physicians ’ Priorities Around AML Decisions in Older Patients Misaligned Patients and Physicians ’ Priorities Around AML Decisions in Older Patients Misaligned
Patients with acute myeloid leukaemia find decision-making around care is often not aligned with their clinician ’s views. Lack of medication options and emotional trauma play a role in poor decision-making.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 24, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Predictors of Late Effects in Young AML Survivors Explored
MONDAY, Nov. 23, 2020 -- Many adolescent and young adult (AYA) survivors of acute myeloid leukemia (AML) experience late effects, with the most common being endocrine, cardiovascular, and respiratory, according to a study published online Nov. 9 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Beat AML: Precision Medicine Superior to SOC Beat AML: Precision Medicine Superior to SOC
Precision medicine therapy proved feasible and superior to standard-of-care (SOC) chemotherapy in patients with acute myeloid leukemia in the Beat AML Master Clinical Trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New video: See how strong IP protections lead to stronger treatments for patients
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP system is what has allowed the American biopharmaceutical industry to become the world leader in new medicine development and has allowed us to make unprecedented strides in treating everything from acute leukemia to hepatitis C and more. (Source: The Catalyst)
Source: The Catalyst - November 9, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Intellectual Property IP Explained Source Type: news

Young survivors of acute myeloid leukemia have long-term complications from treatment
(University of California - Davis Health) Adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications after treatment, a study led by UC Davis Comprehensive Cancer Center researchers has found. The most common complications were cardiovascular, endocrine and respiratory diseases. The complications - known as late effects - were more present among non-white AYA patients and those living in more deprived neighborhoods. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 9, 2020 Category: Cancer & Oncology Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites
Ionizing radiation causes acute radiation syndrome, which leads to hematopoietic, gastrointestinal, and cerebrovascular injuries. We investigated a population of mice that recovered from high-dose radiation to live normal life spans. These "elite-survivors" harbored distinct gut microbiota that developed after radiation and protected against radiation-induced damage and death in both germ-free and conventionally housed recipients. Elevated abundances of members of the bacterial taxa Lachnospiraceae and Enterococcaceae were associated with postradiation restoration of hematopoiesis and gastrointestinal repair. The...
Source: ScienceNOW - October 29, 2020 Category: Science Authors: Guo, H., Chou, W.-C., Lai, Y., Liang, K., Tam, J. W., Brickey, W. J., Chen, L., Montgomery, N. D., Li, X., Bohannon, L. M., Sung, A. D., Chao, N. J., Peled, J. U., Gomes, A. L. C., van den Brink, M. R. M., French, M. J., Macintyre, A. N., Sempowski, G. D. Tags: Immunology, Medicine, Diseases, Online Only r-articles Source Type: news

What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem. Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints. Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Survival Rate for Acute Lymphoblastic Leukemia
Title: Survival Rate for Acute Lymphoblastic LeukemiaCategory: Diseases and ConditionsCreated: 10/23/2020 12:00:00 AMLast Editorial Review: 10/23/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 23, 2020 Category: Cancer & Oncology Source Type: news

' Impressive' Outcomes Sans Chemo in Poor-Prognosis ALL'Impressive' Outcomes Sans Chemo in Poor-Prognosis ALL
Chemo-free targeted therapy yielded high rates of molecular response,"impressive" survival at 18 months with few toxic effects in a phase 2 trial of adults with Ph+ acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 21, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia
             Basel, 19 October 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venclexta was previously granted provisional approval in this setting under the FDA ’s accelerated approval pro...
Source: Roche Media News - October 19, 2020 Category: Pharmaceuticals Source Type: news